We are live on ! Find out more
AKCA

Akcea Therapeutics Inc
AKCA

Delisted

AKCA was delisted on the 9th of October, 2020.

98 hedge funds and large institutions have $287M invested in Akcea Therapeutics Inc in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 19

21% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 24

17% more funds holding

Funds holding: 8498 (+14)

7% more capital invested

Capital invested by funds: $268M → $287M (+$19M)

78% less call options, than puts

Call options by funds: $553K | Put options by funds: $2.47M

Holders
98
Holders Change
+14
Holders Change %
+16.67%
% of All Funds
1.98%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
33
Increased
29
Reduced
24
Closed
19
Calls
$553K
Puts
$2.47M
Net Calls
-$1.92M
Net Calls Change
-$1.76M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$104M -$69.4M -4,894,782 -46%
BlackRock
2
BlackRock
New York
$39.9M -$1.43M -100,698 -4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$24.9M -$1.29M -91,232 -6%
GF
4
Gabelli Funds
New York
$10.9M +$8.51M +599,625 New
Wells Fargo
5
Wells Fargo
California
$8.13M +$5.48M +386,038 +623%
CS
6
Credit Suisse
Switzerland
$7.13M +$5.35M +377,115 +2,409%
BG
7
Bellevue Group
Switzerland
$6.17M -$15.9M -1,122,032 -77%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$5.75M -$198K -13,979 -4%
State Street
9
State Street
Massachusetts
$5.59M -$142K -10,043 -3%
Renaissance Technologies
10
Renaissance Technologies
New York
$4.98M -$370K -26,100 -9%
Northern Trust
11
Northern Trust
Illinois
$4.6M -$137K -9,661 -4%
CS
12
Candriam SCA
Luxembourg
$4.43M +$3.47M +244,395 New
Citigroup
13
Citigroup
New York
$3.99M +$2.9M +204,717 +1,329%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$3.97M -$3.19M -225,122 -51%
WIC
15
Water Island Capital
New York
$3.96M +$3.09M +218,000 New
GI
16
GAMCO Investors
Connecticut
$3.87M +$3.02M +213,107 New
DAM
17
DLD Asset Management
New York
$3.75M +$2.93M +206,864 New
Morgan Stanley
18
Morgan Stanley
New York
$3.55M +$2.43M +171,094 +699%
KC
19
Kellner Capital
New York
$3.52M +$2.75M +194,100 New
GCIA
20
Gabelli & Co Investment Advisers
New York
$2.68M +$2.09M +147,574 New
AA
21
ALPS Advisors
Colorado
$2.35M -$126K -8,889 -6%
Charles Schwab
22
Charles Schwab
California
$2.01M -$944K -66,578 -38%
Nuveen
23
Nuveen
North Carolina
$1.84M +$401K +28,235 +39%
Goldman Sachs
24
Goldman Sachs
New York
$1.33M -$557K -39,275 -35%
Qube Research & Technologies (QRT)
25
Qube Research & Technologies (QRT)
United Kingdom
$1.3M +$785K +55,346 +339%

AKCA Hedge Fund Activity: Q3 2020 in Review

98 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q3 2020, worth a combined $287M — up 7.1% from $268M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new AKCA positions and 19 closed out — a net gain of 14 holders — while 29 added to existing stakes and 24 trimmed.

The largest buyer was Gabelli Funds, opening a new position worth an estimated $8.51M. The largest seller was Fidelity Investments, cutting an estimated $69.4M.

  • 98 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q3 2020, up from 84 in Q2 2020.
  • Funds reported $287M of Akcea Therapeutics Inc stock for Q3 2020, up 7.1% quarter-over-quarter.
  • 33 funds opened new Akcea Therapeutics Inc positions in Q3 2020 and 19 closed out, a net change of +14 holders.
  • The largest Akcea Therapeutics Inc buyer in Q3 2020 was Gabelli Funds, an estimated $8.51M added.
  • The largest Akcea Therapeutics Inc seller in Q3 2020 was Fidelity Investments, an estimated $69.4M sold.

Based on aggregated 13F filings for Q3 2020.